Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials.
Journal: Human vaccines & immunotherapeutics
Published: May 05, 2026
Nipocalimab for the treatment of moderate-to-severe Sjögren's disease: a plain language summary of the DAHLIAS study.
Journal: Expert review of clinical immunology
Published: February 18, 2026
A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 04, 2025
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial.
Journal: Lancet (London, England)
Published: February 28, 2025
FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity.
FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity.
Journal: The Journal of experimental medicine
Published: February 27, 2020
FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Journal: Blood
Published: April 14, 2019
The Neonatal Fc Receptor (FcRn): A Misnomer?
Journal: Frontiers in immunology
Published: March 19, 2019
Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 24, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026